Cardio-oncology

In recent years, cardiac complications arising from cancer treatments (chemotherapy, targeted therapies, radiotherapy) have been recognised as one of the main causes of morbidity and, ultimately, mortality in survivors.

Advances in early detection and the development of new drugs and treatment regimens have undoubtedly increased patient survival (in some cases reaching 5-year survival rates of up to 90%). However, despite this context of ‘therapeutic success’, numerous studies have confirmed an increased risk of medium- and/or long-term cardiovascular complications associated with the use of chemotherapy and/or radiotherapy.

Cardiovascular toxicity secondary to cancer treatments is currently the most common cause of mortality in patients who survive breast cancer. For all these reasons, the Teknon Oncology Institute has launched the first specific unit that allows the best possible cancer treatment to be administered while minimising its cardiovascular effects.

The Cardio-oncology Unit assesses all patients diagnosed with cancer who are going to undergo potentially cardiotoxic therapy and identifies the risk based on the planned treatment, in addition to identifying and monitoring pre-existing cardiovascular risk factors.

The Cardio-Oncology Unit (COU) at Centro Médico Teknon is the result of close multidisciplinary collaboration between the Teknon Oncology Institute and the Teknon Cardiology Institute, two institutes renowned in their respective fields, in a specific unit that allows the best possible oncological treatment to be administered while minimising its cardiovascular effects, ensuring a comprehensive approach and continuous care for cancer patients.

For further information, please contact the Teknon Oncology Institute:

Phone: 93 290 64 71